These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 7476084

  • 21. Imaging of low- and intermediate-grade gliomas.
    Ricci PE, Dungan DH.
    Semin Radiat Oncol; 2001 Apr; 11(2):103-12. PubMed ID: 11285548
    [Abstract] [Full Text] [Related]

  • 22. Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy.
    Preul MC, Caramanos Z, Villemure JG, Shenouda G, LeBlanc R, Langleben A, Arnold DL.
    Neurosurgery; 2000 Feb; 46(2):306-18. PubMed ID: 10690719
    [Abstract] [Full Text] [Related]

  • 23. MR imaging in cerebral gliomas. Tissue component analysis in correlation with histopathology of whole-brain specimens.
    Tovi M, Hartman M, Lilja A, Ericsson A.
    Acta Radiol; 1994 Sep; 35(5):495-505. PubMed ID: 8086262
    [Abstract] [Full Text] [Related]

  • 24. Proton magnetic resonance spectroscopy of normal human brain and glioma: a quantitative in vivo study.
    Tong ZY, Toshiaki Y, Wang YJ.
    Chin Med J (Engl); 2005 Aug 05; 118(15):1251-7. PubMed ID: 16117877
    [Abstract] [Full Text] [Related]

  • 25. Proton magnetic resonance spectroscopy in differentiating glioblastomas from primary cerebral lymphomas and brain metastases.
    Chawla S, Zhang Y, Wang S, Chaudhary S, Chou C, O'Rourke DM, Vossough A, Melhem ER, Poptani H.
    J Comput Assist Tomogr; 2010 Aug 05; 34(6):836-41. PubMed ID: 21084897
    [Abstract] [Full Text] [Related]

  • 26. Moving the needle: Optimizing classification for glioma.
    Verhaak RG.
    Sci Transl Med; 2016 Aug 03; 8(350):350fs14. PubMed ID: 27488893
    [Abstract] [Full Text] [Related]

  • 27. Differentiating diffuse World Health Organization grade II and IV astrocytomas with ex vivo magnetic resonance spectroscopy.
    Vettukattil R, Gulati M, Sjøbakk TE, Jakola AS, Kvernmo NA, Torp SH, Bathen TF, Gulati S, Gribbestad IS.
    Neurosurgery; 2013 Feb 03; 72(2):186-95; discussion 195. PubMed ID: 23147779
    [Abstract] [Full Text] [Related]

  • 28. Subtyping of gliomas of various WHO grades by the application of immunohistochemistry.
    Popova SN, Bergqvist M, Dimberg A, Edqvist PH, Ekman S, Hesselager G, Ponten F, Smits A, Sooman L, Alafuzoff I.
    Histopathology; 2014 Feb 03; 64(3):365-79. PubMed ID: 24410805
    [Abstract] [Full Text] [Related]

  • 29. [Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors].
    Lichy MP, Bachert P, Hamprecht F, Weber MA, Debus J, Schulz-Ertner D, Schlemmer HP, Kauczor HU.
    Rofo; 2006 Jun 03; 178(6):627-33. PubMed ID: 16703499
    [Abstract] [Full Text] [Related]

  • 30. Improved delineation of brain tumors: an automated method for segmentation based on pathologic changes of 1H-MRSI metabolites in gliomas.
    Stadlbauer A, Moser E, Gruber S, Buslei R, Nimsky C, Fahlbusch R, Ganslandt O.
    Neuroimage; 2004 Oct 03; 23(2):454-61. PubMed ID: 15488395
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Characterization of oligodendrogliomas using short echo time 1H MR spectroscopic imaging.
    Rijpkema M, Schuuring J, van der Meulen Y, van der Graaf M, Bernsen H, Boerman R, van der Kogel A, Heerschap A.
    NMR Biomed; 2003 Feb 03; 16(1):12-8. PubMed ID: 12577293
    [Abstract] [Full Text] [Related]

  • 36. Metabolic approach for tumor delineation in glioma surgery: 3D MR spectroscopy image-guided resection.
    Zhang J, Zhuang DX, Yao CJ, Lin CP, Wang TL, Qin ZY, Wu JS.
    J Neurosurg; 2016 Jun 03; 124(6):1585-93. PubMed ID: 26636387
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Evaluation of invasiveness of astrocytoma using 1H-magnetic resonance spectroscopy: correlation with expression of matrix metalloproteinase-2.
    Zhang K, Li C, Liu Y, Li L, Ma X, Meng X, Feng D.
    Neuroradiology; 2007 Nov 03; 49(11):913-9. PubMed ID: 17763847
    [Abstract] [Full Text] [Related]

  • 39. In vivo quantification of the metabolites in normal brain and brain tumors by proton MR spectroscopy using water as an internal standard.
    Tong Z, Yamaki T, Harada K, Houkin K.
    Magn Reson Imaging; 2004 Sep 03; 22(7):1017-24. PubMed ID: 15288143
    [Abstract] [Full Text] [Related]

  • 40. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions.
    Möller-Hartmann W, Herminghaus S, Krings T, Marquardt G, Lanfermann H, Pilatus U, Zanella FE.
    Neuroradiology; 2002 May 03; 44(5):371-81. PubMed ID: 12012120
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.